Assoc Prof David Tan

Affiliations
Senior Consultant, Department of Haematology-Oncology, National University Cancer Institute, Singapore
Senior Consultant, Department of Oncology - Medical & Radiation, Ng Teng Fong General Hospital
Associate Professor, Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore
Profile
Dr David Tan is a medical oncologist and clinician scientist at the National
University Cancer Institute, Singapore. He is an Associate Professor at
the Yong Loo Lin School of Medicine, NUS and Principal Investigator at
the Cancer Science Institute, NUS. He is also Head of the Innovation Transfer
Office at National University Health Systems (NUHS). His primary clinical
and research interests are in gynaecological (ovarian, endometrial and
cervical) cancers and the development of novel anti-cancer therapeutic
agents.
Dr Tan graduated from Guy’s, King’s and St Thomas’ School of Medicine,
University of London, UK with a BSc in Experimental Pathology (1st Class
Honours) and MBBS with Distinction. He undertook training in internal medicine
at Hammersmith Hospital and Guy’s and St Thomas’ Hospitals in London before
being awarded a Cancer Research UK Research Fellowship at The Institute
of Cancer Research in London, where he obtained his PhD in Oncology. He
subsequently completed his specialist training in medical oncology at The
Royal Marsden Hospital in London. After working in the Drug Development
Unit at The Royal Marsden Hospital/ Institute of Cancer Research, he completed
another fellowship at the Princess Margaret Cancer Centre, University of
Toronto, Canada, in Drug Development and Gynaecologic Oncology before returning
back to Singapore.
He is the founding President of the Gynecologic Cancer Group Singapore
(GCGS), which is a national clinical trials network for gynaecologic cancers
in Singapore, and was the inaugural Chairman of the Asia-Pacific Gynaecologic
Oncology Trials (APGOT) Group from 2019-2022. He currently also co-chairs
the Cervical Cancer Research Network (CCRN) of the Gynecologic Cancer InterGroup
(GCIG) and sits on the Gynecologic Cancer InterGroup (GCIG) Executive Board
of Directors.